The catalytic A subunit of cholera toxin (CT-A) is capable of ADP-ribosylating the guanine nucleotidebinding protein, which regulates cell adenylyl cyclase, leading to the life-threatening diarrhea of cholera.
of cholera, vaccines consisting of chemically inactivated CT administered parenterally, or of its immunodominant B-subunit protein administered perorally with killed vibrios, were minimally protective; in the latter instance, the results of an extensive field study suggested that the addition of the B subunit actually reduced the efficacy of the whole-cell vaccine (11) . The B-subunit protein, by itself, has previously been shown to be a less effective immunogen than other forms of CT antigen, including the holotoxin itself (13, 14) . However, the disease cholera is itself an effective immunizing process in which both antitoxic and antibacterial antibodies are produced locally and systemically (27) , having been stimulated by the in vivo-grown vibrios and their products. It CT is a multimeric protein exotoxin. The A ("active") protomer and the pentameric B ("binding") subunits are encoded by a single transcriptional unit, ctxAB (36) . When posttranslationally modified by proteolysis and reduction (21) , the catalytic A1 subunit of CT is capable of ADP-ribosylating 3052 HASE ET AL. the guanine nucleotide-binding protein, which regulates cell adenylyl cyclase, leading to the severe diarrhea of cholera. The catalytic subunit of several ADP-ribosylating bacterial toxins share certain small regions of amino acid sequence identity (20, 41) . is essential for enzymatic activity of pertussis toxin, and substitution of lysine for Arg-9 in the S-1 subunit of pertussis toxin abolishes ADP-ribosyltransferase activity and toxicity without altering a neutralizing epitope (8, 38) . Similarly, the substitution of lysine for Arg-7 in the A subunit of CT, and in the A subunit of the CT-related heat-labile enterotoxin (LT) of Escherichia coli, eliminated ADP-ribosyltransferase activity (9, 29) . Substitution of aspartic acid for Glu-1 10 or Glu-1 12 severely repressed ADP-ribosyltransferase activity of LT (29) . Chemical mutagenesis that resulted in the substitution of lysine for Glu-112 caused a loss of toxicity and ADP-ribosyltransferase activity (46, 47) . The protein did, however, interact with ADP-ribosylation factor (ARF), the 20-kDa guanine nucleotide-binding protein that serves as a GTP-dependent allosteric activator of CT and LT (34) . Jobling and Holmes (24) have recently reported a variety of sitedirected mutations of CT-A that had marked effects on holotoxin assembly and toxicity. To our knowledge, no one has yet substituted mutagenized ctxA for the wild-type gene in Vibrio cholerae.
Employing site-directed mutagenesis, in the present study we have created mutant CT-A subunit genes with codon substitutions for both Arg-7 and Glu-112, changes that eliminated ADP-ribosyltransferase activity. Genes encoding inactive analogs of CT (CT-1* and CT-2*, representing the two major epitypes of CT [13, 14, 31, 39] ) were inserted into the chromosome of wild-type V. cholerae strains, including both serogroup 01 Inaba and Ogawa serotypes of El Tor and classical biotypes and the 0139 (synonym Bengal) serogroup currently epidemic in India and Bangladesh (10, 40) . The resulting recombinant strains may have potential as living attenuated vaccines, and the CT analogs could themselves be useful in conjugate vaccines and in structure-function studies.
MATERIALS AND METHODS
Bacterial strains, plasmids, media, and culture conditions. The bacterial strains and plasmids utilized are described in Table 1 . The E. coli cells were grown at 37°C in Luria-Bertani broth medium (43) . Antibiotics (Sigma Chemical Co., St. Louis, Mo.) were added at the following concentrations (in micrograms per milliliter): ampicillin, 50; kanamycin, 50; chloramphenicol, 10; tetracycline, 12.5 (E. coli) or 5 (V cholerae). V cholerae was cultured in syncase broth (15) for electroporation or toxin production.
DNA preparation, manipulation, and analysis. Plasmid DNA was extracted from E. coli DH5a cells by the alkaline lysis method of Birnboim and Doly (3). V cholerae chromosomal DNA was prepared as described previously (2) . Standard techniques (43) were used in the construction of recombinant plasmids. Restriction enzymes were generally obtained from Promega (Madison, Wis.), and digestions were done with buffers provided by the suppliers under the recommended conditions. Restriction fragments were electrophoresed in horizontal 0.8% agarose gels in TAE buffer (43) and stained with ethidium bromide (0.5 ,ug/ml). Restriction fragments were isolated from low-melting-point agarose (FMC BioProducts, Rockland, Maine) gels, melted at 55°C, and used directly in ligation reactions. Site-directed mutagenesis was performed as described previously (9 Electroporation. The V. cholerae strains were transformed by electroporation, with slight modifications of a published procedure (32) . Bacterial cells were grown to mid-log phase in 20 ml of syncase medium (15) at 37°C, harvested and washed three times in the electroporation buffer (272 mM sucrose, 7 mM Na2HPO4 [pH 7.4], 1 mM MgCl2), and resuspended in 1 ml of the same buffer. After the plasmid DNA was added, the bacteria were subjected to electric shock (Bio-Rad Gene Pulser, 25-pF capacitance, 2.5 kV) and allowed to recover in 1.5 ml of syncase medium at 37°C. The bacteria were pelleted, resuspended in 200 ,ul of medium, and plated on meat extract agar plates containing the appropriate antibiotics.
Recombinant CT analog production. For CT* production, 500-ml flasks containing 100 ml of syncase medium supplemented with antibiotics were inoculated with 2 x 106 viable bacteria per ml and incubated overnight (20 h) at 30°C with shaking. The recombinant toxin analogs were isolated from culture supernatants and partially purified by Al(OH)3 adsorption and elution (18) .
ARF-stimulated NAD:agmatine ADP-ribosyltransferase activity. The NAD:agmatine ADP-ribosyltransferase assay was performed essentially as described previously (34) . Four micrograms of partially purified recombinant toxins was incubated at 30°C for 10 min in 70 mM glycine-30 mM dithiothreitol, pH 8.0. Wild-type CT holotoxin was treated similarly.
Assay mixtures contained 50 mM potassium phosphate, pH 7.5, 5 mM MgCl2, 100 ,uM GTP, 20 mM dithiothreitol, 0.1 mg of ovalbumin per ml, 100 ,uM [adenine-U-'4C]NAD (approximately 100,000 cpm), 3 mM dimyristoylphosphatidylcholine, 0.2% cholate, 10 mM agmatine, 0.5 ,ug of recombinant ARF 6, and 0.5 ,ug of wild-type or recombinant toxin in a 150-pu total volume. After incubation for 1 h at 30°C, 50-pA samples were transferred to columns of AG1-X2, which were washed five times with 1 ml of water each time. All eluates were collected for radioaassay by liquid scintillation counting.
Toxicity. Toxicity was assayed in vitro using Y-1 adrenal tumor cells (42) essentially as described previously (31) . Samples containing up to 100 ng of toxin antigen (as determined by a radial diffusion immunoassay [19] ) were added in duplicate (12) . Monoclonal antibodies (MAbs) against B-subunit proteins used in this study were described previously and included anti-CT-1 (ox-CT-1) and ox-CT-2 classes I, III, and VI, ot-H-LT class II, ao-pDL-3 class IV, and ot-S-LT class V (26) . MAbs KB9 and 8EI 1 against the A subunit of CT-1 were also used (17) .
Microzone electrophoresis. The recombinant proteins were analyzed by using the Microzone cellulose acetate electrophoresis system (Beckman Instruments Inc., Fullerton, Calif.) (6) .
SDS-PAGE and Western blotting (immunoblotting). Samples of proteins were subjected to polyacrylamide gel electrophoresis (PAGE) in 4% stacking and 15% separating polyacrylamide gels and transferred onto nitrocellulose membranes as described previously (7). GM, binding. GM, binding was evaluated by the Ouchterlony double diffusion in gel method. The checkerboard immunoblotting procedure (25) , the GM, modification (26) , and the GM, enzyme-linked immunosorbent assay (GM I-ELISA) have been described (17) . 
RESULTS
Construction of plasmids encoding CT-2* and CT-1*. Plasmid pCT-A* was constructed by subcloning a synthetic oligonucleotide linker with an Arg-7-->Lys codon substitution (CGG--AAG) into the mutated cixA gene containing a Glu-112->Gln (GAA--CAG) mutation, thus combining both codon substitutions. An 8.3-kb PstI fragment carrying the ctxAB genes from V. cholerae 3083, a CT-2 producer, was previously cloned into pBR328 (p3083) (5) . To place the mutated CT-A subunit gene in a functional genetic environment for toxin production, the wild-type ctxA gene of p3083 was replaced with the mutated ctxA * gene by exchange of the analogous 0.8-kb NdeI restriction fragment containing most of the CT-A subunit gene, thus generating p3083*. The CT gene from V cholerae 569B, which produces CT-1, was previously cloned into pBR322 (pJM17) (36 (Fig. 1) . To confirm the presence of both point mutations in the ctiA genes and the successful recombination of the ccxB genes encoding the B subunit of CT-1 in C6706/CT-1*, C7258/ CT-1*, and SG25-1/CT-1*, the entire ctxAB operon was amplified by PCR from both the mutant and parental wild-type strains; DNA fragments of approximately 1.2 kb were amplified, cloned, and partially sequenced. In all mutant strains, codon substitutions for both Arg-7 and Glu-112 were present in the ci&A* genes. As expected, differences in nucleotide sequences between the ctxB genes encoding the B subunits of CT-1 and CT-2 were found: the ctxB genes from C6706/CT-1* C7258/CT-1*, and SG25-1/CT-1* encode His-18 and Thr-47 (CT-1), whereas those of C6706/CT-2*, C7258/CT-2*, and SG25-1/CT-2* encode Tyr-18 and Ile-47 (CT-2) (12, 39 formed with plasmids pCT-1* and pCT-2* for the purpose of producing toxin analogs for analysis. The yields of analog proteins from plasmid-carrying strain JBK70 ranged from approximately 0.15 to 0.25 ,ug/ml. Examination by Western blotting of the toxin analogs, CT-1* and CT-2*, partially purified with AI(OH)3, revealed unnicked A* (28 kDa), A1* (21 kDa), and B (11.5 kDa) protein bands (Fig. 2) . Because CT-1*, CT-2, and CT-2* were rapidly isolated, the A subunit z z was predominantly unnicked (4) . When the toxin analogs were treated overnight at 24°C with 1.8 ,ug of typsin per ml (21), they were fully converted to a nicked form (Fig. 2) .
The partially purified toxin analogs migrated identically to wild-type CT in cellulose acetate membrane electrophoresis, and the single protein bands were stained with both a-A and a-B polyclonal antibodies. To determine whether the amino acid substitutions affected the immunological properties of these toxin analogs, antitoxin MAbs (26) derivatives were blocked by GM, (Fig. 3) . However, the reaction of a-CT-1 class VI MAb was blocked by GM, only with CT-2 and CT-2*. Polyclonal antibodies recognized mutant and wild-type proteins equally well. Thus, the immunological properties of the CT analogs, by these criteria, were identical to those of wild-type toxins. <1 ). V cholerae organisms were recovered in practically pure culture from the intestines of the rabbits challenged with wild-type and recombinant strains.
DISCUSSION
The ultimate goal of this work is the development of a cholera vaccine which is effective (preferably in a single dose), economical, convenient, and suitably nonreactogenic. For reasons which have been discussed elsewhere (13, 14, 27) , none of the many candidate vaccines which have been developed in the past has met all of these criteria; they have been insufficiently potent, too reactogenic, too expensive and inconvenient, or exhibited a combination of these deficiencies. One promising vaccine candidate, CVD103-HgR (a CT-A-CT-B+ mutant of classical Inaba strain 569B), is well tolerated but, like its parent strain, poorly colonizes the gut; high doses are required (33) , and it has a diminished protective efficacy against the more prevalent El Tor biotype (28) . This reduced effectiveness against the El Tor biotype is yet unexplained but could relate to the fact that it is an A-B+ strain (i.e., it has no CT-A antigen); further, the B-subunit protein it produces is of the CT-1 epitype, whereas most El Tor vibrios (except the Gulf Coast clone [personal observations]) produce CT-2. In addition, CVD103-HgR does not produce the cell-associated mannose-sensitive hemagglutinin that is characteristic of El Tor biotype strains (23) and, because of somatic antigen differences, it is likely to be ineffective against the new 0139 serogroup strains.
It is not clear why CT antigens containing A-subunit protein (e.g., the holotoxin or procholeragenoid) elicit stronger immune responses than the B-subunit pentamer (choleragenoid) (37) . The fact that procholeragenoid (a heat-induced aggregate of CT) was minimally toxic, but equally as immunogenic as the holotoxin, would suggest that ADP-ribosyltransferase activity was not responsible for its enhanced immunogenicity. However, these observations are complicated by its high molecular weight and slight residual CT-like activity. CT has been recognized since the pioneer study of Northrup and Fauci (35) codon substitutions in the ctxA* genes and the appropriate ctxB genes. Our observations do not as yet permit the likely conclusion that the original ctxB-1 is retained in the classical biotype CT-2*-producing mutants; i.e., they could conceivably be producing chimeras of CT*-B-1 and CT*-B-2 which could be advantageous. Studies are in progress to enable us to make this determination.
The El Tor and 0139 recombinant strains were avirulent in the infant rabbit animal model. Whether they are suitably avirulent for use in humans can be determined only by trial in volunteers. Previous studies with small numbers of volunteers have demonstrated that Tox-mutants (e.g., JBK70), although diarrheagenic by themselves, elicited significant protection against subsequent challenge with the virulent wild type (28a).
The mechanisms of this protection are not clear, although an antibacterial (anti-LPS) component was presumed to be involved since the challenged volunteers yielded fewer vibrios on coproculture. Whether engineered strains expressing toxin analogs containing both A and B subunits would provide better and more durable homologous immunity remains to be tested. They could potentially also offer better cross-protection against related enterotoxins if A*B is more effective than B alone as an antigen and adjuvant. It is also evident from the recent volunteer studies with Tox-mutants that, even though CT is the factor responsible for the severe, life-threatening diarrhea of cholera, the vibrios have other mechanisms for causing milder forms of diarrhea. CVD110, a mutant from El Tor biotype Ogawa serotype strain E7946 deleted for all known virulence factors, was still capable of causing diarrhea (mean stool volume of 861 ml) in 7 of 10 volunteers (45) . The act of colonization may itself be diarrheagenic; alternatively,
another, yet undiscovered, cholera enterotoxin may be responsible. As (22) .
